



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of :
Sewing, Andreas : Group Art Unit: 1616
Serial No.: 09/885,287 : Examiner: Gollamudi S
Filed: June 21, 2006 :
For: A PROCESS FOR THE COATING FOR METALLIC IMPLANT MATERIALS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☐ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☐ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☒ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- 08/31/2006 MAHMED1 00000006 09885287
- ☒ a final rejection under 37 C.F.R. 1.111⁹² FC:1806 180.00 OP
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

☐ a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR

☒ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

☐ a final action under 37 C.F.R. § 1.113;

☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2);
OR

☐ a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

☐ the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

☐ Each item of information contained in this information disclosure statement was a first cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or

☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).

- ☐ Copies of materials listed were cited in an international search report dated _____.
- ☐ Not required by 37 CFR § 1.98 (US patent references).
- ☒ Copies of the materials listed are attached.

Non-English Language References

- ☐ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- ☒ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
- X = document of particular relevance when it is taken alone
 Y = document of particular relevance when it is combined with another such document
 A = document defining the general state of the art
 O = non-written disclosure
 P = intercalated document
 T = document cited to understand the theory or principle underlying the invention
 E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
 D = cited in the application
 L = cited for another reason
 & = publication of member of same patent family
- ☒ Translation of other relevant information on foreign search report


Other Information

Payment of Fees Due (If Any):

- ☒ A check for \$180.00 covering the fee identified above is attached.
- ☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Jennifer J. Branigan, Reg. No. 40,921
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No. MAIKO-0033

Date: August 30, 2006

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 09/885287 |
| Filing Date | 06/21/2001 |
| First Named Inventor | Andreas SEWING et al. |
| Group Art Unit | 1616 |
| Examiner Name | Gollamudi |
| Attorney Docket Number | MAIKO 33 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | 5,508,267 | | Czernuszka et al. | 4/16/1996 | |
| | 1 | 5,068,122 | | Kokubo et al. | 11/26/1991 | |
| | 2 | 4,713,076 | | Draenert | 12/15/1987 | |
| | 3 | 6,384,197 | | Weis et al. | 5/7/2002 | |
| | 4 | 6,384,195 | | Weis et al. | 5/7/2002 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | EP | 0 389 713 | | | 10/3/1990 | | 1 |
| | | DE | 3414924 | | | 10/31/1985 | | 2 |
| | | DE | 198 12 714 | | | 9/30/1999 | | 3 |
| | | DE | 198 12 713 | | | 9/30/1999 | | 4 |
| | | DE | 198 11 900 | | | 9/23/1999 | Abstract | |
| | | DE | 34 09 372 | | | 9/19/1985 | Abstract | |
| | | DE | 196 43 5555 | | | 4/30/1998 | | 5 |
| | | WO | 9213984 | | | 8/30/1992 | | 6 |

Examiner
Signature


Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|----------------|
| Application Number | 09/885,287 |
| Filing Date | 06/21/01 |
| First Named Inventor | Andreas SEWING |
| Group Art Unit | 1616 |
| Examiner Name | Gollamudi |
| Attorney Docket Number | MAIKO 33 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | European International Search Report issued 12-5-01 in EP 01 11 2667. | |
| | | Office Communication dated 3-14-01 | |
| | | L. Floquet et al., "Le comportement biologique in vitro d'un alliage TiNb30 traité avec hydroxyapatite..." Rev. Stomatol. Chir. Maxillofac., (1997), 98, Sup. 1, pgs. 47-49. | |
| | | M.J. Filiaggi, et al., "Post-plasma-spraying heat treatment of the HA coating/Ti-6Al-4V implant system", Journal of Biomedical Materials Res., (1993), Vol. 27, pgs. 191-198. | |
| | | K.A. Gross, "In Vitro Changes of Hydroxyapatite Coatings", The International Journal of Oral & Maxillofacial Implants, pgs. 589-597 | |
| | | M. Shirkhanzadeh, "Direct formation of nanophase hydroxyapatite on cathodically polarized electrodes", Journal of Materials Science: Materials in Medicine 9, (1998), pgs. 67-72. | |
| | | C.Y. Yang, "Bond degradation at the plasma-sprayed HA coating/Ti-6Al-4V alloy interface: an in vitro study", Journal of Materials Science: Materials in Medicine 6, (1995), pgs. 258-265. | |
| | | P. Schaffner, et al., "Inducted tissue integration of bone implants by coating with bone selective RGD-peptides", Journal of Materials Science: Materials in Medicine, 10, (1999), pgs 837-839 | |
| | | | |
| | | | |
| | | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.